MLTX

SEC source: 0001213900-25-084492 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,389

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-084492 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-061752 · ownership.xml · derivative · entry 3

Moukheibir Catherine · CIK 0001772130 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Class A ordinary shares, par value $0.0001 per share · 23,500 shares

Expires 2032-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options are fully vested.

SEC source: 0001213900-25-061752 · ownership.xml · nonDerivative · entry 2

Moukheibir Catherine · CIK 0001772130 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-25-061752 · ownership.xml · nonDerivative · entry 1

Moukheibir Catherine · CIK 0001772130 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000921895-25-001730 · form407422010_06092025.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · 10% owner

BVF I GP LLC · CIK 0001803805 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · 10% owner

BVF II GP LLC · CIK 0001803806 · Director · 10% owner

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 6,682

Underlying: Class A Ordinary Shares, $0.0001 par value · 6,682 shares

Expires 2035-06-05

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to Spike Loy's continued service to the Issuer.

F8 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F8 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001213900-25-052367 · ownership.xml · derivative · entry 1

Xavier Ramnik · CIK 0001920780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,682

Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-25-052368 · ownership.xml · derivative · entry 1

Loy Spike · CIK 0001920549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,682

Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-25-052370 · ownership.xml · derivative · entry 1

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,682

Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-25-052366 · ownership.xml · derivative · entry 1

Moukheibir Catherine · CIK 0001772130 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,682

Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-25-052365 · ownership.xml · derivative · entry 1

Phillips Andrew John · CIK 0001921956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,682

Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-25-019674 · ownership.xml · nonDerivative · entry 1

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,078,577

F1 · kind: Represents shares of restricted stock that vest in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-019672 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 616,666

F1 · kind: Represents shares of restricted stock that vest in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-019673 · ownership.xml · derivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,273

Underlying: Class A ordinary shares, par value $0.0001 per share · 139,273 shares

Expires 2035-02-27

F1 · derivative.exercise_date: This option represents a right to purchase a total of 139,273 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-005686 · ownership.xml · derivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,508

Underlying: Class A ordinary shares, par value $0.0001 per share · 111,949 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-005686 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,367

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-005686 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,930

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-084492 · ownership.xml · derivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,052

Underlying: Class A ordinary shares, par value $0.0001 per share · 48,978 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0000921895-24-002263 · form407422010_10082024.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · 10% owner

BVF I GP LLC · CIK 0001803805 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · 10% owner

BVF II GP LLC · CIK 0001803806 · Director · 10% owner

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,287,768

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-24-002263 · form407422010_10082024.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · 10% owner

BVF I GP LLC · CIK 0001803805 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · 10% owner

BVF II GP LLC · CIK 0001803806 · Director · 10% owner

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,168,838

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-24-002263 · form407422010_10082024.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · 10% owner

BVF I GP LLC · CIK 0001803805 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · 10% owner

BVF II GP LLC · CIK 0001803806 · Director · 10% owner

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,235,089

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001213900-24-086271 · ownership.xml · nonDerivative · entry 1

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,980

F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $53.00 to $55.34. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-050828 · ownership.xml · derivative · entry 1

Xavier Ramnik · CIK 0001920780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares

Expires 2034-06-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-24-050824 · ownership.xml · derivative · entry 1

Loy Spike · CIK 0001920549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares

Expires 2034-06-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-24-050826 · ownership.xml · derivative · entry 1

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares

Expires 2034-06-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-24-050835 · ownership.xml · derivative · entry 1

Moukheibir Catherine · CIK 0001772130 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares

Expires 2034-06-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001213900-24-050833 · ownership.xml · derivative · entry 1

Phillips Andrew John · CIK 0001921956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,688

Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares

Expires 2034-06-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0000921895-24-001377 · form407422010_06102024.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · 10% owner

BVF I GP LLC · CIK 0001803805 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · 10% owner

BVF II GP LLC · CIK 0001803806 · Director · 10% owner

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,688

Underlying: Class A Ordinary Shares, $0.0001 par value · 7,688 shares

Expires 2034-06-06

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Spike Loy's continued service to the Issuer.

F7 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F7 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 3

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,982,814

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 2

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,987,554

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,981

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,925,573

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 1

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,043,619

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,957,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,502

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F6 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.15 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,986,974

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.225 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-016544 · ownership.xml · nonDerivative · entry 1

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,106,429

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.025 to $55.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 3

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,107,554

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.115 to $59.21. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.14 to $59.09. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,987,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.06 to $59.09. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 6

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F8 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 5

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,997,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F7 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 2

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,127,554

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.335 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F6 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.18 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 3,007,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.10 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 1

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,147,554

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.185 to $63.95. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 3,017,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-23-097671 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 520,903

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2023.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $57.53 to $59.27. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.